Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies
Résumé
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B-C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV-HCV bivalent vaccine-bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.
Mots clés
WHO
World Health Organization HCV
hepatitis C virus DAAs
directacting antivirals HBV
hepatitis B virus HBsAg
hepatitis B virus S envelope protein β-gal
β-galactosidase OD
optical density HCVcc
hepatitis C virus in cell culture FFU
focusforming unit
World Health Organization
HCV
hepatitis C virus
DAAs
directacting antivirals
HBV
hepatitis B virus
HBsAg
hepatitis B virus S envelope protein
β-gal
β-galactosidase
OD
optical density
HCVcc
hepatitis C virus in cell culture
FFU
Domaines
Sciences du Vivant [q-bio]Origine | Fichiers produits par l'(les) auteur(s) |
---|